Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blast-phase myeloproliferative neoplasm

Detalles Bibliográficos
Autores principales: Gangat, Naseema, Ilyas, Rimal, McCullough, Kristen, Begna, Kebede H., Al-Kali, Aref, Patnaik, Mrinal M., Litzow, Mark R., Hogan, William J., Mangaonkar, Abhishek, Alkhateeb, Hassan, Shah, Mithun V., Elliott, Michelle A., Foran, James M., Badar, Talha, Palmer, Jeanne M., Hanson, Curtis A., Pardanani, Animesh, Tefferi, Ayalew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10153526/
https://www.ncbi.nlm.nih.gov/pubmed/36519330
http://dx.doi.org/10.3324/haematol.2022.282019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10153526/
https://www.ncbi.nlm.nih.gov/pubmed/36519330
http://dx.doi.org/10.3324/haematol.2022.282019

Ejemplares similares